Outset Medical will release Q2 2026 financial results on August 6, followed by a conference call with executives.
Quiver AI Summary
Outset Medical, Inc. announced it will release its second-quarter 2026 financial results on August 6, 2026, after market close. Following the release, CEO Leslie Trigg and CFO Renee Gaeta will host a conference call at 1:30 p.m. PT to discuss the results. Interested parties can access the call through the company's website or register for telephone participation. Outset Medical focuses on transforming dialysis care with its innovative Tablo® Hemodialysis System, which is FDA-cleared and widely used across healthcare facilities in the U.S., integrating water purification and dialysate production to improve operational, clinical, and financial outcomes.
Potential Positives
- Outset Medical is set to release its second-quarter financial results, indicating transparency and ongoing communication with investors.
- The upcoming conference call will feature key executives, promoting engagement and clarity on the company's financial performance and strategic direction.
- The Tablo® Hemodialysis System is already trusted by over 1,000 healthcare facilities, highlighting market acceptance and a solid foundation for growth.
- Outset's innovative technology aims to significantly reduce the cost and complexity of dialysis, positioning the company favorably in a critical healthcare market.
Potential Negatives
- The announcement of the financial results comes after the close of trading, which may indicate potential concerns about the company's performance that it does not aim to address until then.
FAQ
What are Outset Medical's financial results release date?
Outset Medical will release its financial results for the second quarter 2026 on August 6, 2026.
Who will host the conference call for the financial results?
Leslie Trigg, CEO, and Renee Gaeta, CFO, will host the conference call on August 6, 2026.
How can I access the conference call?
You can access the conference call via the “Investors” section of Outset Medical's website or register online for telephone participation.
What technology does Outset Medical offer for dialysis?
Outset Medical offers the Tablo® Hemodialysis System, designed to simplify and reduce the cost of dialysis treatments.
How has Outset Medical impacted healthcare facilities?
Outset Medical's technology is trusted by over 1,000 U.S. healthcare facilities, facilitating millions of dialysis treatments.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Quiver Alerts
Receive OM Data Alerts
Get market-moving data, filings, and signals for OM in real time.
Sign Up
$OM Insider Trading Activity
$OM insiders have traded $OM stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $OM stock by insiders over the last 6 months:
- RENEE GAETA (Chief Financial Officer) sold 17,672 shares for an estimated $87,299
- LESLIE TRIGG (Chair and CEO) has made 0 purchases and 2 sales selling 6,806 shares for an estimated $24,005.
- JOHN L. BROTTEM (General Counsel) has made 0 purchases and 2 sales selling 5,480 shares for an estimated $19,281.
- MARC NASH (EVP Operations R&D & Service) has made 0 purchases and 2 sales selling 3,399 shares for an estimated $11,940.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$OM Revenue
$OM had revenues of $27.9M in Q1 2026. This is a decrease of -6.35% from the same period in the prior year.
You can track OM financials on Quiver Quantitative's OM stock page.
You can access data on OM stock through the Quiver Quantitative API.
$OM Hedge Fund Activity
We have seen 55 institutional investors add shares of $OM stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALYESKA INVESTMENT GROUP, L.P. removed 1,614,582 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $6,199,994
- BML CAPITAL MANAGEMENT, LLC added 1,359,021 shares (+250.2%) to their portfolio in Q1 2026, for an estimated $5,218,640
- WOODLINE PARTNERS LP removed 1,033,418 shares (-77.9%) from their portfolio in Q1 2026, for an estimated $3,968,325
- AQR CAPITAL MANAGEMENT LLC added 627,922 shares (+348.1%) to their portfolio in Q1 2026, for an estimated $2,411,220
- STRATOS WEALTH PARTNERS, LTD. added 200,546 shares (+inf%) to their portfolio in Q1 2026, for an estimated $770,096
- UBS GROUP AG added 179,339 shares (+245.1%) to their portfolio in Q1 2026, for an estimated $688,661
- RENAISSANCE TECHNOLOGIES LLC added 176,870 shares (+391.3%) to their portfolio in Q1 2026, for an estimated $679,180
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$OM Analyst Ratings
Wall Street analysts have issued reports on $OM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/12/2026
To track analyst ratings and price targets for $OM, check out Quiver Quantitative's $OM forecast page.
$OM Price Targets
Multiple analysts have issued price targets for $OM recently. We have seen 2 analysts offer price targets for $OM in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Eric Winmill from Scotiabank set a target price of $3.0 on 06/15/2026
- Marie Thibault from BTIG set a target price of $15.0 on 02/12/2026
Full Release
SAN JOSE, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter 2026 after the close of trading on Thursday, August 6, 2026.
On the same day, at 1:30 p.m. PT (4:30 p.m. ET), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss the results.
Conference Call Details
Those interested in accessing the live or archived version of the conference call can visit the “Investors” section of the Outset Medical website at
https://investors.outsetmedical.com
. Those interested in participating in the call via telephone may register online at
this link
. Once registered, participants will receive a dial-in number and unique PIN to join the call. Participants are encouraged to register more than 15 minutes before the start of the call.
About Outset Medical, Inc.
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo
®
Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit
www.outsetmedical.com
.
Investor Contact
investors@outsetmedical.com
Read full article here »
View the Zacks #1 Rank List
Outset Medical to Report Second Quarter 2026 Financial Results on August 6 and Host Conference Call
Outset Medical will release Q2 2026 financial results on August 6, followed by a conference call with executives.
Quiver AI Summary
Outset Medical, Inc. announced it will release its second-quarter 2026 financial results on August 6, 2026, after market close. Following the release, CEO Leslie Trigg and CFO Renee Gaeta will host a conference call at 1:30 p.m. PT to discuss the results. Interested parties can access the call through the company's website or register for telephone participation. Outset Medical focuses on transforming dialysis care with its innovative Tablo® Hemodialysis System, which is FDA-cleared and widely used across healthcare facilities in the U.S., integrating water purification and dialysate production to improve operational, clinical, and financial outcomes.
Potential Positives
Potential Negatives
FAQ
What are Outset Medical's financial results release date?
Outset Medical will release its financial results for the second quarter 2026 on August 6, 2026.
Who will host the conference call for the financial results?
Leslie Trigg, CEO, and Renee Gaeta, CFO, will host the conference call on August 6, 2026.
How can I access the conference call?
You can access the conference call via the “Investors” section of Outset Medical's website or register online for telephone participation.
What technology does Outset Medical offer for dialysis?
Outset Medical offers the Tablo® Hemodialysis System, designed to simplify and reduce the cost of dialysis treatments.
How has Outset Medical impacted healthcare facilities?
Outset Medical's technology is trusted by over 1,000 U.S. healthcare facilities, facilitating millions of dialysis treatments.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OM Insider Trading Activity
$OM insiders have traded $OM stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $OM stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$OM Revenue
$OM had revenues of $27.9M in Q1 2026. This is a decrease of -6.35% from the same period in the prior year.
You can track OM financials on Quiver Quantitative's OM stock page.
You can access data on OM stock through the Quiver Quantitative API.
$OM Hedge Fund Activity
We have seen 55 institutional investors add shares of $OM stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$OM Analyst Ratings
Wall Street analysts have issued reports on $OM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
To track analyst ratings and price targets for $OM, check out Quiver Quantitative's $OM forecast page.
$OM Price Targets
Multiple analysts have issued price targets for $OM recently. We have seen 2 analysts offer price targets for $OM in the last 6 months, with a median target of $9.0.
Here are some recent targets:
Full Release
SAN JOSE, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter 2026 after the close of trading on Thursday, August 6, 2026.
On the same day, at 1:30 p.m. PT (4:30 p.m. ET), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss the results.
Conference Call Details
Those interested in accessing the live or archived version of the conference call can visit the “Investors” section of the Outset Medical website at https://investors.outsetmedical.com . Those interested in participating in the call via telephone may register online at this link . Once registered, participants will receive a dial-in number and unique PIN to join the call. Participants are encouraged to register more than 15 minutes before the start of the call.
About Outset Medical, Inc.
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo ® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com .
Investor Contact
investors@outsetmedical.com
Read full article here »